Tiziana life sciences to present at the 2022 biotechnology innovation organization annual convention to discuss recent updates to ongoing clinical programs

New york, june 06, 2022 (globe newswire) -- tiziana life sciences ltd (nasdaq: tlsa) ("tiziana" or the "company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via novel routes of administration today announced that its chief executive officer and chief scientific officer, kunwar shailubhai, ph.d., will present at the biotechnology innovation organization (bio) annual convention taking place at the san diego convention center, monday june 13 - thursday, june 16, 2022. his presentation will be primarily focused on the recent clinical updates on nasal administration of foralumab, a fully human anti-cd3 monoclonal antibody, for treatment of patients with secondary progressive multiple sclerosis. he will also provide an update on the initiation of phase 1b trial with ‘first-ever' oral capsules of foralumab for treatment of patients with mild-to-moderately active crohn's disease. company management will also be participating in one-on-one meetings throughout the conference.
TLSA Ratings Summary
TLSA Quant Ranking